StockData
Processa Pharmaceuticals, Inc. logo

Processa Pharmaceuticals, Inc. (PCSA) stock

PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$1.70−0.03 (-1.73%)

Close on Nov 18, 2026Market cap $4.75MP/E –Yield –

Processa Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Processa Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2016 was $5.00K. For fiscal 2016 it was $5.00K. The highest annual figure on record is $124.48K in fiscal 2013.

Annual gross profit

PeriodPeriod endValueChange
FY2016Dec 31, 2016$5.00K–
FY2015Dec 31, 2015-$12.45K-130.8%
FY2014Dec 31, 2014$40.41K-67.5%
FY2013Dec 31, 2013$124.48K+111.4%
FY2012Dec 31, 2012$58.89K–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–
Q2 FY2016Jun 30, 2016$0–
Q1 FY2016Mar 31, 2016$5.00K–

More Processa Pharmaceuticals figures

See a number that looks wrong?